Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.

NEXT STORY
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
PREV STORY
AZTherapies Announces Leadership Transition, Appointing Marc de Garidel Chief Executive Officer and Member of the Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis

TOKYO and SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: ...

author_avatar
NASDAQ Market News

Vaxil Appoints a Special Advisor to the Board of Directors

author_avatar
NASDAQ Market News

Evoke to Participate in the Brean Capital 2015 Life Sciences Summit

SOLANA BEACH, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a ...

author_avatar
NASDAQ Market News